Alpha IVF Group completed its transfer from the ACE Market to the Main Market of Bursa Malaysia on Tuesday signaling a major push to expand its regional footprint.
The fertility specialist, which has grown from three to eight full-fledged centres since March 2024, aims to use this new listing to attract institutional investors and consolidate the fragmented fertility sector across Southeast Asia, [theedgemalaysia.com] reported.
The transition to the Main Market was driven by requests from institutional funds that were previously restricted from investing in the company’s ACE Market securities, according to [businesstoday.com.my]. For the financial year ending May 31, 2026, the group reported revenue of RM198.58 million and a net profit of RM53.63 million, [theedgemalaysia.com] noted. As of that date, the firm held RM134.3 million in cash and short-term investments with no borrowings.
“We’ve always wanted to deliver stronger financial performance and sustainable returns for our shareholders,” said Dato’ Dr Colin Lee Soon Soo, co-founder and Group Managing Director, in an interview with [businesstoday.com.my].
The group currently operates 13 facilities across five countries, including satellite clinics in Indonesia and sales offices in China.
Lee remains focused on maintaining clinical quality, utilizing a proprietary “system of systems” that standardizes protocols and laboratory capabilities across the network, [theedgemalaysia.com] reported. This approach is intended to ensure consistent success rates as the company scales.
| Financial Metric | FY2026 Total |
|---|---|
| Revenue | RM198.58 million |
| Net Profit | RM53.63 million |
| Cash and Short-term Investments | RM134.3 million |
International Patients Drive Revenue Growth
The group’s financial results for the 2026 fiscal year highlight a major reliance on cross-border demand for its medical services. According to reports, international patients generated RM120.1 million, which accounts for 67.2% of the Malaysian operations’ revenue and approximately 60% of the total group revenue.

This regional focus remains a core component of the company’s operational model. Group Managing Director Dato’ Dr Colin Lee Soon Soo maintains a rigorous schedule to oversee these international interests, recently returning from visits to clinics in Indonesia to ensure the cohesion of the group’s expanding footprint.
“The danger is that we expand too fast and we're not able to control the quality,” Dato' Dr Colin Lee Soon Soo said.
Dividends Reflect Strong Balance Sheet
The transition to the Bursa Malaysia Main Market was accompanied by a stable capital position that the company intends to use for its future development.
Following the conclusion of the 2026 financial year, the board declared total dividends of 1.10 sen per share. The management team views these financial fundamentals as essential to supporting their long-term goal of scaling the network from the current eight full-fledged centres to ten by mid-2027.
Bursa Malaysia categorizes its Main Market as a venue for established corporations, whereas the ACE Market operates as a sponsor-driven platform for smaller firms with growth potential. Under 2026 guidelines, the Main Market mandates stricter financial thresholds, such as an aggregate after-tax profit of at least RM30 million over three years, compared to the ACE Market’s lack of a minimum profit requirement.
This transfer allows companies to attract institutional investors, as many funds are constrained by internal mandates that restrict them to the more mature Main Market. By moving to this board, firms signal their transition to a higher regulatory standard, providing the stability and governance depth required by large-scale institutional capital that remains inaccessible to entities listed on the ACE Market.
Indonesia represents a major growth target for the group. While the country’s population of roughly 280 million could theoretically support 350,000 IVF cycles annually, current market performance sits between 13,000 and 14,000 cycles, [businesstoday.com.my] reported. To tap into this, Alpha IVF is developing a facility in the Sanur Special Economic Zone in Bali, which is expected to begin operations by mid-2027.
Closer to home, the group is preparing to open a centre in Johor Bahru by the end of 2026. This facility is positioned to capture demand from Singaporean patients seeking alternatives to local treatment costs, [businesstoday.com.my] noted.
“Over the next 10 years, we envision Alpha IVF reaching RM1 billion in revenue and helping bring tens of thousands of IVF babies into the world,” Lee said, as reported by [theedgemalaysia.com].
Related reading
- Neandertal Gene Variant Linked to Smaller Occipital Lobe and Lower Schizophrenia Risk
- Dr. Julieta Quesada: Co-Parents Can Help Manage Labor Pain With Support Techniques
- UK Faces Trade Dilemma as EU Rules Risk Excluding British EVs from Single Market (archynewsy.com)
- The Australian Share Market Suffered Its Worst Week (time.news)